Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF, FRA:31R). reports that AdvisorShares Investments LLC, a leading sponsor of actively managed exchange-traded funds (ETFs), has included the company in the inaugural launch of its AdvisorShares Psychedelics ETF (PSIL).
The ETF invests in the emerging psychedelic drugs sector, offering exposure to biotechnology, pharmaceutical, and life sciences companies leading the way in this nascent industry.
The ETF includes 16 publicly listed companies offering investors exposure to companies who are leading the way in the emerging psychedelics space.
READ: Revive Therapeutics expands clinical stage pipeline with Ganoderma lucidum license deal
“We are pleased to be included in the inaugural launch of the PSIL ETF as it provides further validation of our pharmaceutical psychedelics strategy in pursuing novel uses, formulations and delivery forms of psilocybin for the treatment of mental health and neurological conditions,” said Revive CEO Michael Frank in a statement.
The ETF commenced trading on September 16, 2021, debuting on the New York Stock Exchange under ticker symbol PSIL.
The Ontario-based company is also advancing the development of psychedelic medicine with psilocybin-based therapeutics to fight addictions and depression.
Revive has also joined the fight against the coronavirus (COVID-19) disease, which is caused by the SARS-CoV-2 virus, by repurposing its long-established, US government-approved rheumatoid arthritis treatment Bucillamine as a possible treatment for infected patients suffering from inflammation in their lungs.
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham